IRIDEX Corporation (IRIX)
| Market Cap | 18.17M |
| Revenue (ttm) | 52.68M |
| Net Income (ttm) | -4.44M |
| Shares Out | 17.31M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,437 |
| Open | 1.065 |
| Previous Close | 1.080 |
| Day's Range | 1.020 - 1.065 |
| 52-Week Range | 0.869 - 1.648 |
| Beta | 0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retino... [Read more]
Financial Performance
In fiscal year 2025, IRIDEX's revenue was $52.68 million, an increase of 8.23% compared to the previous year's $48.67 million. Losses were -$4.44 million, -50.20% less than in 2024.
Financial StatementsNews
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and ac...
IRIDEX Earnings Call Transcript: Q4 2025
Revenue grew 8% to $52.7M in 2025 with strong Q4 growth and positive adjusted EBITDA. Cost reductions and operational streamlining led to positive cash flow, while 2026 guidance projects 1–5% growth excluding Middle East sales.
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
Iridex Announces Plans to Relocate Headquarters
MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
IRIDEX Transcript: Sidoti's Year End Virtual Investor Conference
The company is leveraging innovative laser technologies and strong clinical data to expand in both retina and glaucoma markets, with a focus on operational efficiency and margin improvement. Recent cost reductions, product launches, and a robust replacement cycle support a positive financial outlook.
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and acc...
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and acc...
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and acc...
IRIDEX Earnings Call Transcript: Q3 2025
Third quarter revenue grew 8% year-over-year to $12.5 million, with improved Adjusted EBITDA and reduced operating expenses. Gross margin was impacted by a one-time inventory write-down, but underlying profitability and cash flow trends remain positive.
Iridex Reports Third Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025
MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
MOUNTAIN VIEW, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
IRIDEX Earnings Call Transcript: Q2 2025
Q2 2025 saw 7% year-over-year and 14% sequential revenue growth, reduced operating expenses by 28%, and positive adjusted EBITDA. Strong Pascal system sales drove retina segment growth, while cost controls and operational efficiencies improved financial health.
Iridex Reports Second Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and acc...
IRIDEX Earnings Call Transcript: Q1 2025
Revenue grew to $11.9M in Q1 2025, with positive adjusted EBITDA and improved gross margin. Cost reductions and a $10M investment strengthened the balance sheet, while growth in glaucoma products offset a slight retina revenue decline.
Iridex Reports First Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and proc...
Iridex to Report First Quarter 2025 Financial Results on May 13, 2025
MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
IRIDEX Transcript: Status Update
Recent cost reductions have led to positive adjusted EBITDA and improved cash flow, with continued revenue growth in both retina and glaucoma segments. A $10 million strategic investment from Novel Inspiration supports operational improvements, potential acquisitions, and a focus on long-term value creation.
Iridex to Host Strategic Vision Call on April 16, 2025
MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
IRIDEX Earnings Call Transcript: Q4 2024
Q4 2024 saw revenue growth, improved gross margin, and positive adjusted EBITDA, driven by cost reductions and a strategic $10M investment from Novel Innovations. Glaucoma product sales rose, while retina sales dipped slightly. Industry M&A and LCD changes shape a positive 2025 outlook.
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
Iridex Announces Strategic Investment in the Company
MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for ...